Phase II trial of fenretinide in advanced renal carcinoma.
OBJECTIVE
Fenretinide, a synthetic form of retinoid, induced apoptosis even in chemotherapy resistant cell lines. A phase II study was hence conducted to evaluate toxicity and efficacy of fenretinide in metastatic renal cancer.


METHODS
Eligibility included unresectable or metastatic renal cell carcinoma (RCC), adequate organ function and Zubrod performance status < or =2. Prior immunotherapy and a maximum of one prior chemotherapy regimen were allowed. Fenretinide was administered at a dose of 900 mg/m(2) twice daily orally for 7 days in a 21-day cycle. Toxicity was assessed at the start of each cycle, and response every 2 cycles.


RESULTS
Nineteen eligible patients enrolled of which fifteen had visceral/bone metastases. Seventeen patients had prior nephrectomy and 11 had prior immunotherapy. 76 cycles of therapy were delivered. Therapy was very well tolerated with few severe toxicities consisting of thrombosis in 1 individual and grade 3 fatigue, nausea and diarrhea in 1 patient. 5 patients had grade 2 nyctalopia and 3 patients had transient grade 2 visual toxicity. No objective responses were noted. Stable disease was seen in seven of nineteen cases (37%, 90% C.I. 0.21-0.59). Median time to progression was 1.5 months and median duration of stable disease was 5.8 months (90% C.I. 3.0-8.4). Median survival was 10 months. Tumor fenretinide levels were obtained in three patients and were in the lower end of the therapeutic range.


CONCLUSIONS
Fenretinide was well tolerated but demonstrated minimal activity that was consistent with results of intratumoral drug measurements. Strategies are needed that will increase systemic and tumor levels of fenretinide.
Vaishampayan
Ulka
U
Division of Oncology, Wayne State University/Karmanos Cancer Institute, Detroit, MI, USA.
Heilbrun
Lance K
LK
Parchment
Ralph E
RE
Jain
Vikash
V
Zwiebel
James
J
Boinpally
Ramesh R
RR
LoRusso
Patricia
P
Hussain
Maha
M
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D017313:Fenretinide / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D008297:Male; D008875:Middle Aged
D000970:Antineoplastic Agents; D017313:Fenretinide
Cancer Res. 1999 May 15;59(10):2493-8
10344763
J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16
10655437
Eur J Cancer Clin Oncol. 1989 May;25(5):805-8
2525470
Leukemia. 2002 Apr;16(4):463-72
11960323
J Cell Biochem Suppl. 1995;23:80-6
8747381
Blood. 1995 Jan 15;85(2):359-67
7811993
Biometrics. 1982 Mar;38(1):143-51
7082756
Biochem Biophys Res Commun. 1996 Jul 25;224(3):837-42
8713132
Mol Pharmacol. 2003 Mar;63(3):565-73
12606763
Cancer Res. 1989 Nov 1;49(21):6149-52
2529028
Int J Oncol. 1998 Jul;13(1):145-9
9625816
Cancer Res. 1993 Dec 15;53(24):6036-41
8261419
Clin Cancer Res. 2003 Jun;9(6):2032-9
12796365
J Clin Oncol. 1995 Aug;13(8):1950-7
7636535
J Clin Oncol. 2001 Mar 15;19(6):1664-70
11250995
J Natl Cancer Inst. 1995 Nov 15;87(22):1674-80
7473815
J Biol Regul Homeost Agents. 2003 Jan-Mar;17(1):98-114
12757024
J Natl Cancer Inst. 1994 Aug 17;86(16):1245-7
8040893
J Natl Cancer Inst. 1985 Nov;75(5):871-5
2932587
Drugs. 2001;61(7):909-18
11434448
J Clin Oncol. 2000 Aug;18(16):2972-80
10944130
J Interferon Cytokine Res. 2000 Sep;20(9):787-94
11032398
N Engl J Med. 1997 Oct 9;337(15):1021-8
9321529
J Cell Biochem Suppl. 1993;17F:255-61
8412202